By Dr Tonia Mezzini
For many women, a diagnosis of Polycystic Ovary Syndrome (PCOS) has long come with confusion, frustration, and often, years of being dismissed. But now, something significant has shifted.
PCOS has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), and while it may sound like a subtle change, it represents a profound step forward in how we understand, diagnose, and care for women. And in my view, it’s long overdue.
For decades, the name “polycystic ovary syndrome” has been misleading. It suggested that the condition was primarily about ovarian cysts, yet many women with PCOS don’t have cysts at all. Worse still, it narrowed the focus of care to fertility and reproduction, overlooking the broader, whole-body impact this condition can have. The new name changes that narrative.
Polyendocrine metabolic ovarian syndrome acknowledges what clinicians and patients have been saying for years: this is not just an ovarian condition. It is a complex, multi-system disorder involving hormones, metabolism, and long-term health. And that matters, Because names shape understanding. And understanding shapes care.
PMOS affects approximately 1 in 8 women worldwide, making it one of the most common hormonal conditions we see. Yet despite its prevalence, it has been underdiagnosed, misunderstood, and often minimised.
Many women spend years seeking answers and underlying metabolic issues like insulin resistance, inflammation, and increased risk of type 2 diabetes or cardiovascular disease can go unrecognised.
The shift to PMOS is a powerful acknowledgement of this broader picture. It tells women: your symptoms are real, valid, and interconnected. It tells clinicians: look beyond the ovaries. And importantly, it opens the door to better, more holistic care.
Another important aspect of this change is the removal of stigma. The word “cystic” has caused unnecessary fear and confusion for many patients. It has also contributed to misdiagnosis, as healthcare providers historically looked for cysts as a defining feature, when in reality, they are not required for diagnosis.
By reframing the condition, we move away from outdated definitions and towards a more accurate, compassionate understanding.
This change didn’t happen overnight. It followed more than a decade of global collaboration between researchers, clinicians, and crucially, patients themselves. Thousands of women contributed their lived experiences to help shape a name that better reflects what this condition truly is. That alone is worth celebrating.
Because for the first time, many women will feel seen in the name of their diagnosis.
Of course, a name change is just the beginning. It won’t instantly fix gaps in care or eliminate the challenges women face in navigating their health. But it does set a new standard, and encourages earlier diagnosis. It supports more comprehensive treatment approaches, and it validates the lived experience of millions of women who have long felt misunderstood.
In clinical practice, I see firsthand how empowering it can be when women finally understand what’s happening in their bodies. Not just in terms of fertility, but in energy, mood, metabolism, skin, and overall wellbeing. PMOS gives us a language that reflects that complexity, and with better language comes better care.
For women living with this condition, this is more than a rebrand. It’s recognition.
Recognition that this is not “just a period problem.” Recognition that it affects the whole body, across the lifespan. Recognition that women deserve better answers, and better support.
The name change helps doctors and patients to better understand why managing diet and exercise are so important and how medications such as metformin and GLP-1 medications can be game changing. It also helps us to understand why the humble Pill, is not just for contraception, but cycle control and an important part of medical care
of this complex condition. Your doctor might also talk to you about spironolactone, in addition to the Pill, as a way to lower testosterone and improve acne, reduce facial hair and scalp hair loss with PMOS.
As we move forward, my hope is that this shift continues to drive meaningful change in research, education, and clinical care. Women’s health deserves to be taken seriously fully, not partially.
And this is a powerful step in the right direction.